Characterization and evaluation of synthetic riluzole with β-cyclodextrin and 2,6-di-O-methyl-β-cyclodextrin inclusion complexes

Carbohydrate Polymers

Volumn 129, Issue , 2015, Pages 9-16

  Wang, Lili ^a   Li, Shanshan ^a   Tang, Peixiao ^a   Yan, Jin ^a   Xu, Kailin ^a   Li, Hui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

2; 6 Di O methyl cyclodextrin; Hepatotoxicity; Inclusion complex; Riluzole; Solubilization; Cyclodextrin

Indexed keywords

SOLUBILITY;

CYCLODEXTRIN INCLUSION COMPLEXES; HEPATOTOXICITY; INCLUSION COMPLEX; PHARMACEUTICAL APPLICATIONS; PHASE-SOLUBILITY STUDIES; RILUZOLE; SOLUBILIZATION; STABILITY CONSTANTS;

CYCLODEXTRINS;

BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; HEPTAKIS(2,6-O-DIMETHYL)BETA-CYCLODEXTRIN; POWDER; RILUZOLE;

ANIMAL; CELL DEATH; CELL LINE; CELL SURVIVAL; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG EFFECTS; HUMAN; INFRARED SPECTROSCOPY; KINETICS; POWDER; PROTON NUCLEAR MAGNETIC RESONANCE; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; THERMODYNAMICS; X RAY DIFFRACTION;

ANIMALS; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL DEATH; CELL LINE; CELL SURVIVAL; HUMANS; KINETICS; MICROSCOPY, ELECTRON, SCANNING; POWDERS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; RILUZOLE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 84929087907     PISSN: 01448617     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carbpol.2015.04.046     Document Type: Article

References (40)

1. G. Bensimon, L. Lacomblez, and V.F. Meininger A controlled trial of riluzole in amyotrophic lateral sclerosis New England Journal of Medicine 330 9 1994 585 591
2. R. Bruno, N. Vivier, G. Montay, A. éLe Liboux, L.K. Powe, and J.-C. Delumeau et al. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis Clinical Pharmacology & Therapeutics 62 5 1997 518 526
3. R. Carrier, L. Miller, and I. Ahmed The utility of cyclodextrins for enhancingoral bioavailability Journal of Control Release 123 2007 78 99
4. A. Ciobanu, I. Mallard, D. Landy, G. Brabie, D. Nistor, and S. Fourmentin Retention of aroma compounds from Mentha piperita essential oil by cyclodextrins and crosslinked cyclodextrin polymers Food Chemistry 138 1 2013 291 297
5. P. Dandawate, K. Vemuri, E.M. Khan, M. Sritharan, and S. Padhye Synthesis, characterization and anti-tubercular activity of ferrocenyl hydrazones and their β-cyclodextrin conjugates Carbohydrate Polymers 108 2014 135 144
6. M.E. Davis, and M.E. Brewster Cyclodextrin-based pharmaceutics: Past, present and future Nature Reviews Drug Discovery 3 12 2004 1023 1035
7. M. Di Cagno, T. Terndrup Nielsen, K. Lambertsen Larsen, J. Kuntsche, and A. Bauer-Brandl β-Cyclodextrin-dextran polymers for the solubilization of poorly soluble drugs International Journal of Pharmaceutics 468 1 2014 258 263
8. A. Doble The pharmacology and mechanism of action of riluzole Neurology 47 6 Suppl. 4 1996 233S 241S
9. L. Gao, D. Zhang, and M. Chen Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system Journal of Nanoparticle Research 10 5 2008 845 862
10. Y.A. Gao, Z.H. Li, J.M. Du, B.X. Han, G.Z. Li, and W.G. Hou et al. Preparation and characterization of inclusion complexes of β-cyclodextrin with ionic liquid Chemistry - A European Journal 11 20 2005 5875 5880
11. A. Garg, B. Gupta, R. Prakash, and S. Singh Preparation and characterization of hydroxypropyl-BETA-cyclodextrin inclusion complex of eugenol: Differential pulse voltammetry and 1H-NMR Chemical and Pharmaceutical Bulletin 58 10 2010 1313 1319
12. I. Ghosh, S. Bose, R. Vippagunta, and F. Harmon Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth International Journal of Pharmaceutics 409 1 2011 260 268
13. R.J. Glisoni, M.L. Cuestas, V.L. Mathet, J.R. Oubiña, A.G. Moglioni, and A. Sosnik Antiviral activity against the hepatitis C virus (HCV) of 1-indanone thiosemicarbazones and their inclusion complexes with hydroxypropyl-β-cyclodextrin European Journal of Pharmaceutical Sciences 47 3 2012 596 603
14. R.G. Grossman, M.G. Fehlings, R.F. Frankowski, K.D. Burau, D.S. Chow, and C. Tator et al. A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury Journal of Neurotrauma 31 3 2014 239 255
15. R.S. Lacomblez, L. Bensimon, G. Meininger, V. Leigh, and P.P. Guillet Dose-ranging study of riluzole in amyotrophic lateral sclerosis/riluzole study group II The Lancet 347 9013 1996 1425 1431
16. T. Higuchi, and K.A. Connors Phase-solubility techniques Advances in Analytical Chemistry and Instrumentation 4 2 1965 117 212
17. Z. Huang, S. Tian, X. Ge, J. Zhang, S. Li, and M. Li et al. Complexation of chlorpropham with hydroxypropyl-β-cyclodextrin and its application in potato sprout inhibition Carbohydrate Polymers 107 2014 241 246
18. T. Loftsson, and M.E. Brewster Cyclodextrins as functional excipients: Methods to enhance complexation efficiency Journal of Pharmaceutical Sciences 101 9 2012 3019 3032
19. T. Loftsson, and D. Duchene Cyclodextrins and their pharmaceutical applications International Journal of Pharmaceutics 329 1 2007 1 11
20. Y.L. Loukas, P. Jayasekera, and G. Gregoriadis Novel liposome-based multicomponent systems for the protection of photolabile agents International Journal of Pharmaceutics 117 1 1995 85 94
21. Y.L. Loukas, V. Vraka, and G. Gregoriadis Use of a nonlinear least-squares model for the kinetic determination of the stability constant of cyclodextrin inclusion complexes International Journal of Pharmaceutics 144 2 1996 225 231
22. V.A. Marcolino, G.M. Zanin, L.R. Durrant, M.D.T. Benassi, and G. Matioli Interaction of curcumin and bixin with β-cyclodextrin: Complexation methods, stability, and applications in food Journal of Agricultural and Food Chemistry 59 7 2011 3348 3357
23. P.J. Marsac, T. Li, and L.S. Taylor Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters Pharmaceutical Research 26 1 2009 139 151
24. J.I. Pérez-Martínez, J. Ginés, E. Morillo, and J. Moyano H-nuclear magnetic resonance and phase solubility studies of the stoichiometries in 2, 4-D: α-And β-cyclodextrins inclusion complexes Journal of Inclusion Phenomena and Macrocyclic Chemistry 37 1-4 2000 171 178
25. V. Patel, and J. Sarai Synergistic effect of hydrotrope and surfactant on solubility and dissolution of atorvastatin calcium: Screening factorial design followed by ratio optimization Indian Journal of Pharmaceutical Sciences 76 6 2014 483
26. N.E. Polyakov, T.V. Leshina, T.A. Konovalova, E.O. Hand, and L.D. Kispert Inclusion complexes of carotenoids with cyclodextrins: 1HNMR, EPR, and optical studies Free Radical Biology and Medicine 36 7 2004 872 880
27. J. Pratt, J. Rataud, F. Bardot, M. Roux, J.-C. Blanchard, and P.M. Laduron et al. Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia Neuroscience Letters 140 2 1992 225 230
28. G. Schwartz, and M.G. Fehlings Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: Improved behavioral and neuroanatomical recovery with riluzole Journal of Neurosurgery: Spine 94 2 2001 245 256
29. G. Schwartz, and M.G. Fehlings Secondary injury mechanisms of spinal cord trauma: A novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole Progress in Brain Research 137 2002 177 190
30. I. Singh, and H.Y. Aboul-Enein Pharmaceutical applications of cyclodextrins FABAD Journal of Pharmaceutical Sciences 30 4 2005 214 221
31. V.J. Stella, and K.W. Nti-Addae Prodrug strategies to overcome poor water solubility Advanced Drug Delivery Reviews 59 7 2007 677 694
32. L. Szente Cyclodextrins J. Szejtli, T. Osa, Comprehensive supramolecular chemistry 1996 Pergamon Oxford, UK
33. T. Tao, Y. Zhao, J. Wu, and B. Zhou Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement International Journal of Pharmaceutics 367 1-2 2009 109 114
34. K. Uekama, F. Hirayama, and T. Irie Cyclodextrin drug carrier systems Chemical Reviews 98 5 1998 2045 2076
35. M. Üner Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): Their benefits as colloidal drug carrier systems Die Pharmazie - An International Journal of Pharmaceutical Sciences 61 5 2006 375 386
36. M.A. Vandelli, B. Ruozi, F. Forni, A. Mucci, G. Salvioli, and E. Galli A solution and solid state study on 2-hydroxypropyl-β-cyclodextrin complexation with hyodeoxycholic acid Journal of Inclusion Phenomena and Macrocyclic Chemistry 37 1-4 2000 237 251
37. M.A. Vandelli, G. Salvioli, A. Mucci, R. Panini, L. Malmusi, and F. Forni 2-Hydroxypropyl-β-cyclodextrin complexation with ursodeoxycholic acid International Journal of Pharmaceutics 118 1 1995 77 83
38. R.O. Williams III, V. Mahaguna, and M. Sriwongjanya Characterization of an inclusion complex of cholesterol and hydroxypropyl-β-cyclodextrin European Journal of Pharmaceutics and Biopharmaceutics 46 3 1998 355 360
39. C. Yuan, Z. Jin, and X. Xu Inclusion complex of astaxanthin with hydroxypropyl-β-cyclodextrin: UV, FTIR, 1H NMR and molecular modeling studies Carbohydrate Polymers 89 2 2012 492 496
40. L. Zhang, S. Lerner, W.V. Rustrum, and G.A. Hofmann Electroporation-mediated topical delivery of vitamin C for cosmetic applications Bioelectrochemistry and Bioenergetics 48 2 1999 453 461